ArticleACS omega2022
Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)-
Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Antitumor Activity of s-Triazine Derivatives: A Systematic Review.Molecules (Basel, Switzerland) · 2023Pooled it
- Design and Synthesis of Novel Morpholine-Derived Nitrogen-Rich Scaffolds as Multifunctional Anticancer and Antibacterial Agents: Biological Evaluation and Computational Studies.Pharmaceutics · 2026Article
- Investigation of metformin analogues in targeting signaling molecules of head and neck cancer pathways by computational approaches.Scientific reports · 2026Article
- Synthesis of azole-linkedNanoscale advances · 2026Article
- Design, synthesis,RSC advances · 2025Article
- Symmetrical di-substituted phenylamino-RSC advances · 2025Article
- Synthesis and DNA binding studies of novel triazine-isatin hybrids: experimental and computational insights.RSC advances · 2025Article
- Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Article
- Reproducible generation of human liver organoids (HLOs) on a pillar plate platformLab on a chip · 2024Article
- Bis(dimethylpyrazolyl)-aniline-Royal Society open science · 2024Article
- Recent biological applications of heterocyclic hybrids containingRSC advances · 2023Review
- Article
- Acetic Acid Mediated for One-Pot Synthesis of Novel PyrazolylPharmaceutics · 2022Article
- Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors.Frontiers in chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we synthesized a newseries of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.